Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Characterization of the immune basis for reduced type I interferon and proinflammatory cytokine production in serologically active clinically quiescent systemic lupus erythematosus

EF 2013-14

Résumé
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks cells and tissues in the body, resulting in inflammation and tissue damage. SLE can affect any part of the body, but mainly affects the skin, joints, heart, lungs, kidneys and nervous system. According to the Lupus Foundation of America, approximately 50,000 Canadians and 5 million people worldwide are living with lupus. Women account for 70-90% of patients, with an onset between the ages of 16 and 55 years. The course of SLE is highly variable and is characterized by periods of flares, interspersed with periods of remission. Some patients experience a relatively mild disease, while others can have a serious progression that can lead to significant and potentially life-threatening damage to organs, such as the kidneys, brain, heart and lungs. Despite advances in our understanding of SLE, the etiology and outcome remain largely unknown; however, genetic, environmental, and hormonal influences all contribute to its development. These factors lead to a breakdown of the body’s ability to discriminate between itself and its environment, resulting in a cascade of events that triggers autoimmunity. In SLE, the most common feature is production of antibodies against components of our DNA. When these antibodies are bound to DNA, they form what is called an immune complex. These immune complexes deposit in multiple organs, leading to inflammation and damage. Current treatments for SLE are not uniformly effective in all patients and have considerable toxicity. One of the major challenges faced when treating SLE is the variability in the clinical manifestations between patients and over time. Currently, there are no biomarkers that accurately stratify patients with regard to potential flares of disease activity. Although the levels of antibodies against DNA typically fluctuate with disease activity, there is a subset of patients that maintain high levels of these antibodies for sustained periods of time in the absence of clinical activity. Since the current dogma places immune complexes in a central role in disease pathogenesis, the sustained absence of disease activity in these patients (termed serologically active clinically quiescent or SACQ) is perplexing. While previous studies have shown that there is no difference between these patients and those that are both serologically active and clinically active in the production of pathogenic antibodies, a number of factors that cause inflammation were found to be significantly increased in the plasma of clinically active patients as compared to SACQ patients. Since immune complexes are the major inducers of these inflammatory factors through stimulation of immune cells known as dendritic cells, we hypothesize that clinical inactivity in SACQ patients results from an inability of their dendritic cells to produce inflammatory factors in response to immune complexes. By examining how the immune system in SACQ patients prevents inflammatory factor production, the proposed research will provide insight into the immune mechanisms that modulate disease activity in response to antibody production and may ultimately lead to elucidation of potential targets for new treatments.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311721
Name
Kim Nam Yun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of the immune basis for reduced type I interferon and proinflammatory cytokine production in serologically active clinically quiescent systemic lupus erythematosus
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibodies; Autoimmunity; Immune Complexes; Neutrophil Extracellular Traps; Plasmacytoid Dendritic Cells; Proinflammatory Cytokines; Serologically Active Clinically Quiescent Lupus; Systemic Lupus Erythematosus; Type I Interferon
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks cells and tissues in the body, resulting in inflammation and tissue damage. SLE can affect any part of the body, but mainly affects the skin, joints, heart, lungs, kidneys and nervous system. According to the Lupus Foundation of America, approximately 50,000 Canadians and 5 million people worldwide are living with lupus. Women account for 70-90% of patients, with an onset between the ages of 16 and 55 years. The course of SLE is highly variable and is characterized by periods of flares, interspersed with periods of remission. Some patients experience a relatively mild disease, while others can have a serious progression that can lead to significant and potentially life-threatening damage to organs, such as the kidneys, brain, heart and lungs. Despite advances in our understanding of SLE, the etiology and outcome remain largely unknown; however, genetic, environmental, and hormonal influences all contribute to its development. These factors lead to a breakdown of the body’s ability to discriminate between itself and its environment, resulting in a cascade of events that triggers autoimmunity. In SLE, the most common feature is production of antibodies against components of our DNA. When these antibodies are bound to DNA, they form what is called an immune complex. These immune complexes deposit in multiple organs, leading to inflammation and damage. Current treatments for SLE are not uniformly effective in all patients and have considerable toxicity. One of the major challenges faced when treating SLE is the variability in the clinical manifestations between patients and over time. Currently, there are no biomarkers that accurately stratify patients with regard to potential flares of disease activity. Although the levels of antibodies against DNA typically fluctuate with disease activity, there is a subset of patients that maintain high levels of these antibodies for sustained periods of time in the absence of clinical activity. Since the current dogma places immune complexes in a central role in disease pathogenesis, the sustained absence of disease activity in these patients (termed serologically active clinically quiescent or SACQ) is perplexing. While previous studies have shown that there is no difference between these patients and those that are both serologically active and clinically active in the production of pathogenic antibodies, a number of factors that cause inflammation were found to be significantly increased in the plasma of clinically active patients as compared to SACQ patients. Since immune complexes are the major inducers of these inflammatory factors through stimulation of immune cells known as dendritic cells, we hypothesize that clinical inactivity in SACQ patients results from an inability of their dendritic cells to produce inflammatory factors in response to immune complexes. By examining how the immune system in SACQ patients prevents inflammatory factor production, the proposed research will provide insight into the immune mechanisms that modulate disease activity in response to antibody production and may ultimately lead to elucidation of potential targets for new treatments.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kim, Nam Yun
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~